Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eastern Cooperative Oncology Group
Neonc Technologies, Inc.
Children's Oncology Group
University of Nebraska
Massive Bio, Inc.
Pfizer
Barbara Ann Karmanos Cancer Institute